| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fb38ebd40c70e97cc5f1519c6699162 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 |
| filingDate |
2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82e123a1a587a7e390f7371f5ca4806e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14eadc4de31ce9c5a7191beb3b357454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56284160000eeaa9c5372e665af45408
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5fe890b2dae1674f2eb3383e7a2402c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ea25d7c943694eeb4fbe0448c21e4fc |
| publicationDate |
2021-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112843222-A |
| titleOfInvention |
Application of ANKRD22 protein in the preparation of products for treating or delaying autoimmune diseases |
| abstract |
The invention discloses the application of ANKRD22 protein in the preparation of products for treating or delaying autoimmune diseases. The present invention has found through research that ANKRD22 recombinant protein can reduce the expression of IL-23 derived from dendritic cells in skin tissue, truncate the formation of inflammatory microenvironment in the initial stage of psoriasis, thereby reducing the induction of IL-23-Th17/γδT17 axis The proliferation of epidermal cells and the production of autoantigens and chemokines can effectively block the vicious cycle of inflammation and delay symptoms such as epidermal hyperplasia and desquamation, and can better prevent recurrence after drug withdrawal and reduce the risk of opportunistic infections. Therefore, ANKRD22 recombinant protein can be used in the treatment of autoimmune diseases, including psoriasis and inflammatory bowel disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116139280-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114113630-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114113630-A |
| priorityDate |
2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |